Multiple myeloma starts in the plasma cells inside your bone marrow. People with multiple myeloma have high levels of certain ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

But after a seemingly random finger fracture, his doctor tested him for elevated protein levels in his blood and told him he had a form of cancer called multiple myeloma. It was sort of an out-of ...

The modified cells recognise and bind to B-cell maturation antigen (BCMA), a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of cells ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

leading to the overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. 2 Today, treatment for multiple myeloma often involves an intensive combination ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Response of myeloma to treatment was defined as ≥ 50% decrease of myeloma protein in the serum and ≥ 90% reduction of Bence-Jones proteinuria. Differences among various groups were compared ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).